StockMacro
Company, fund or insider

Help

Menu

Ionis Pharmaceuticals

$26.58 -65% in 6 monthsMarket cap $4.4B

IONS on XNAS, Health Care, Ionis Pharmaceuticals, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 64% over 12 months and 40% in a month while quarterly revenue rose 55%.

  • BadShort interest is 13% of shares, 8.4 days to cover
  • BadFree cash flow was negative $616M over the last 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Industry
Pharmaceutical preparations (Health Care)
Employees
1,402
Website
ionis.com
Listed
Nasdaq, US
Last results
9 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $242.7M, net loss $110.0M.
Quarter to 31 Dec 2021: revenue $440.0M, net income $224.6MQuarter to 31 Dec 2021: revenue $440.0M, net income $224.6MQuarter to 31 Mar 2022: revenue $141.9M, net income -$65.2MQuarter to 31 Mar 2022: revenue $141.9M, net income -$65.2MQuarter to 30 Jun 2022: revenue $133.8M, net income -$105.1MQuarter to 30 Jun 2022: revenue $133.8M, net income -$105.1MQuarter to 30 Sep 2022: revenue $159.8M, net income -$47.0MQuarter to 30 Sep 2022: revenue $159.8M, net income -$47.0MQuarter to 31 Dec 2022: revenue $151.9M, net income -$52.4MQuarter to 31 Dec 2022: revenue $151.9M, net income -$52.4MQuarter to 31 Mar 2023: revenue $130.5M, net income -$124.3MQuarter to 31 Mar 2023: revenue $130.5M, net income -$124.3MQuarter to 30 Jun 2023: revenue $188.4M, net income -$85.3MQuarter to 30 Jun 2023: revenue $188.4M, net income -$85.3MQuarter to 30 Sep 2023: revenue $144.2M, net income -$147.4MQuarter to 30 Sep 2023: revenue $144.2M, net income -$147.4MQuarter to 31 Dec 2023: revenue $324.5M, net income -$9.3MQuarter to 31 Dec 2023: revenue $324.5M, net income -$9.3MQuarter to 31 Mar 2024: revenue $119.5M, net income -$142.8MQuarter to 31 Mar 2024: revenue $119.5M, net income -$142.8MQuarter to 30 Jun 2024: revenue $225.2M, net income -$66.3MQuarter to 30 Jun 2024: revenue $225.2M, net income -$66.3MQuarter to 30 Sep 2024: revenue $133.8M, net income -$140.5MQuarter to 30 Sep 2024: revenue $133.8M, net income -$140.5MQuarter to 31 Dec 2024: revenue $226.6M, net income -$104.3MQuarter to 31 Dec 2024: revenue $226.6M, net income -$104.3MQuarter to 31 Mar 2025: revenue $131.6M, net income -$146.9MQuarter to 31 Mar 2025: revenue $131.6M, net income -$146.9MQuarter to 30 Jun 2025: revenue $452.0M, net income $123.6MQuarter to 30 Jun 2025: revenue $452.0M, net income $123.6MQuarter to 30 Sep 2025: revenue $156.7M, net income -$128.6MQuarter to 30 Sep 2025: revenue $156.7M, net income -$128.6MQuarter to 31 Dec 2025: revenue $203.3M, net income -$229.4MQuarter to 31 Dec 2025: revenue $203.3M, net income -$229.4MQuarter to 31 Mar 2026: revenue $246.1M, net income -$92.5MQuarter to 31 Mar 2026: revenue $246.1M, net income -$92.5MQuarter to 30 Jun 2026: revenue $267.9M, net income -$114.6MQuarter to 30 Jun 2026: revenue $267.9M, net income -$114.6MQuarter to 30 Sep 2026: revenue $242.7M, net income -$110.0MQuarter to 30 Sep 2026: revenue $242.7M, net income -$110.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $452.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$242.7M-$110.0M
30 Jun 2026$267.9M-$114.6M
31 Mar 2026$246.1M-$92.5M
31 Dec 2025$203.3M-$229.4M
30 Sep 2025$156.7M-$128.6M
30 Jun 2025$452.0M$123.6M
31 Mar 2025$131.6M-$146.9M
31 Dec 2024$226.6M-$104.3M
30 Sep 2024$133.8M-$140.5M
30 Jun 2024$225.2M-$66.3M
31 Mar 2024$119.5M-$142.8M
31 Dec 2023$324.5M-$9.3M
30 Sep 2023$144.2M-$147.4M
30 Jun 2023$188.4M-$85.3M
31 Mar 2023$130.5M-$124.3M
31 Dec 2022$151.9M-$52.4M
30 Sep 2022$159.8M-$47.0M
30 Jun 2022$133.8M-$105.1M
31 Mar 2022$141.9M-$65.2M
31 Dec 2021$440.0M$224.6M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $960.1M $967.0M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -0.7% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$546.5M -$256.3M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$3.32 -$1.69
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 98.2% 98.8% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -58.8% -28.8% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -56.9% -26.5% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -108% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$616.3M -$302.7M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $1.9B $2.2B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $630.9M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – -$1.6B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.36
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 4.6 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 11.2 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Ionis PharmaceuticalsIONS (this company) $4.4Bloss4.6-0.7%-56.9%
Edgewise TherapeuticsEWTX $4.4B4.3–––
Travere TherapeuticsTVTX $4.5Bloss6.9+49%-18.7%
Cogent BiosciencesCOGT $4.6Bloss–––
PTC TherapeuticsPTCT $4.7Bloss4.1-35%-9.2%
Dianthus TherapeuticsDNTH $4.8Bloss–––

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+55%

$242.7M vs $156.7M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+141%

$12.7M vs $5.3M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$87K

bought $148K, sold $61K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-9.1%

458 13F filers vs 504

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

175.1M shares held by 13F filers (30 Sep 2026) of 166.5M outstanding (3 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

13%

21.2M shares sold short (30 Oct 2026) of 166.5M outstanding (3 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.4

21.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+2.5%

20.7M shares sold short in the report before, 21.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

50%

50% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 56%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$590K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

23

23 articles in the last 7 days; its usual week has 7 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.3×

23 articles in the last 7 days; its usual week has 7.

Price $26.58 on 20 Nov 2026, -64% over 12 months (12-month range $26.58 to $86.50)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $114.0M in the last 12 months (the 12 months before: -$78.6M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 5 published in the last 12 months, -44% on the 12 months before.
Revenue per quarter. Revenue $242.7M in the latest quarter, +55% on a year earlier.
Capital spending per quarter. Capital spending $12.7M in the latest quarter, +141% on a year earlier.
Institutional holders (13F filers). 458 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.
Lobbying spend. Lobbying spend: $590K published in the last 12 months, +48% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
8 Jun 20268-K and other filingsDirector or officer change
8 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Mar 20268-K and other filingsDirector or officer change
9 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 93 vs usual 45 (2025-12-31); 2.3x the same period a year earlier
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 100 vs usual 45 (2025-09-30); 2.2x the same period a year earlier
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 70 vs usual 43 (2025-06-30); 1.6x the same period a year earlier
31 Jul 2025Sharp changeQuarterly revenue change: quarterly revenue change, 452.0M vs usual 166.3M (2025-06-30); 2.0x the same period a year earlier
12 Jun 20258-K and other filingsDirector or officer change
12 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Oct 2024Sharp changeLobbying on a new issue: lobbying on a new issue: MMM, TAX (2024-09-30)
7 Aug 2024Lobbying filingnew lobbying registration (LMH STRATEGIC SOLUTIONS)
7 Aug 2024Lobbying filingnew lobbying registration (in-house)
29 Feb 20248-K and other filingsDirector or officer change
27 Feb 2024Sharp changeQuarterly revenue change: quarterly revenue change, 324.5M vs usual 148.0M (2023-12-31); 2.1x the same period a year earlier
14 Dec 20238-K and other filingsDirector or officer change
14 Dec 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Aug 2023Sharp changeQuarterly revenue change: quarterly revenue change, 188.4M vs usual 137.9M (2023-06-30); 1.4x the same period a year earlier
15 Aug 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 12.0M vs usual 3.7M (2023-06-30); 3.6x the same period a year earlier
4 Aug 20238-K and other filingsA major agreement ended
9 May 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 10.5M vs usual 3.3M (2023-03-31); 3.9x the same period a year earlier
4 Nov 20228-K and other filingsA major agreement ended
24 Oct 20228-K and other filingsCompleted an acquisition or asset sale
28 Jul 20228-K and other filingsDelisting notice or listing transfer
16 Jul 20228-K and other filingsDirector or officer change
16 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Mar 20228-K and other filingsDirector or officer change
18 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Mar 2022Sharp changeQuarterly revenue change: quarterly revenue change, 440.0M vs usual 139.5M (2021-12-31); 1.5x the same period a year earlier
31 Jan 20228-K and other filingsA major agreement ended
26 Nov 20218-K and other filingsDirector or officer change
26 Nov 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Apr 2022: -$302K published
Month from 1 Jul 2022: -$51K published
Month from 1 Aug 2022: -$45.2 published
Month from 1 Sep 2022: -$20K published
Month from 1 Jan 2023: -$2.9M published
Month from 1 Feb 2023: -$1.9M published
Month from 1 Apr 2023: -$260K published
Month from 1 May 2023: -$262K published
Month from 1 Jul 2023: -$937K published
Month from 1 Aug 2023: -$27K published
Month from 1 Sep 2023: -$749K published
Month from 1 Oct 2023: -$176K published
Month from 1 Nov 2023: -$100K published
Month from 1 Dec 2023: -$14.0M published
Month from 1 Jan 2024: -$6.6M published
Month from 1 Feb 2024: -$2.4M published
Month from 1 Apr 2024: -$204K published
Month from 1 May 2024: -$256K published
Month from 1 Jun 2024: -$645K published
Month from 1 Jul 2024: -$681K published
Month from 1 Aug 2024: -$117K published
Month from 1 Sep 2024: -$32K published
Month from 1 Oct 2024: -$2K published
Month from 1 Nov 2024: -$809K published
Month from 1 Dec 2024: $181K published
Month from 1 Jan 2025: -$3.0M published
Month from 1 Feb 2025: -$2.2M published
Month from 1 Mar 2025: -$5K published
Month from 1 Apr 2025: -$216K published
Month from 1 May 2025: $478K published
Month from 1 Jul 2025: -$48K published
Month from 1 Aug 2025: -$1.7M published
Month from 1 Sep 2025: -$32.2M published
Month from 1 Oct 2025: -$21.1M published
Month from 1 Nov 2025: -$18.8M published
Month from 1 Dec 2025: -$2.3M published
Month from 1 Jan 2026: -$15.4M published
Month from 1 Feb 2026: -$20.0M published
Month from 1 Mar 2026: -$47.4M published
Month from 1 Apr 2026: -$3.4M published
Month from 1 May 2026: -$7.0M published
Month from 1 Jun 2026: -$13.3M published
Month from 1 Jul 2026: -$6.4M published
Month from 1 Aug 2026: $1.1M published
Month from 1 Oct 2026: -$61K published
Month from 1 Nov 2026: $148K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 3 published
Quarter from 1 Oct 2022: 2 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 2 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Apr 2024: 2 published
Quarter from 1 Jul 2024: 2 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Apr 2025: 5 published
Quarter from 1 Jul 2025: 3 published
Quarter from 1 Oct 2025: 1 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Jul 2026: 3 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $440.0M, +52% on a year earlier; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $141.9M, +27% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $133.8M, +6.4% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $159.8M, +20% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $151.9M, -65% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $130.5M, -8.0% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $188.4M, +41% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $144.2M, -9.7% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $324.5M, +114% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $119.5M, -8.4% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $225.2M, +20% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $133.8M, -7.2% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $226.6M, -30% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $131.6M, +10% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $452.0M, +101% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $156.7M, +17% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $203.3M, -10% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $246.1M, +87% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $267.9M, -41% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $242.7M, +55% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $2.5M, -51% on a year earlier; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $2.7M, +53% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $3.3M, -23% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $5.5M, +67% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $4.1M, +65% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $10.5M, +287% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $12.0M, +260% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $2.1M, -61% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Mar 2024: $4.5M, -57% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $6.2M, -48% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $9.1M, +323% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $25.5M; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $12.6M, +180% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $12.3M, +97% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $5.3M, -42% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $21.3M, -16% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $21.8M, +73% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $16.1M, +31% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $12.7M, +141% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 309; public on 14 Feb 2022
31 Mar 2022 report: 306; public on 16 May 2022
30 Jun 2022 report: 324; public on 15 Aug 2022
30 Sep 2022 report: 311; public on 14 Nov 2022
31 Dec 2022 report: 308; public on 14 Feb 2023
31 Mar 2023 report: 286; public on 15 May 2023
30 Jun 2023 report: 276; public on 14 Aug 2023
30 Sep 2023 report: 283; public on 14 Nov 2023
31 Dec 2023 report: 335; public on 14 Feb 2024
31 Mar 2024 report: 339; public on 15 May 2024
30 Jun 2024 report: 330; public on 14 Aug 2024
30 Sep 2024 report: 334; public on 14 Nov 2024
31 Dec 2024 report: 341; public on 14 Feb 2025
31 Mar 2025 report: 330; public on 15 May 2025
30 Jun 2025 report: 348; public on 14 Aug 2025
30 Sep 2025 report: 408; public on 14 Nov 2025
31 Dec 2025 report: 476; public on 17 Feb 2026
31 Mar 2026 report: 481; public on 15 May 2026
30 Jun 2026 report: 504; public on 14 Aug 2026
30 Sep 2026 report: 458; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Oct 2024: $80K published
Quarter from 1 Jan 2025: $80K published
Quarter from 1 Apr 2025: $90K published
Quarter from 1 Jul 2025: $90K published
Quarter from 1 Oct 2025: $140K published
Quarter from 1 Jan 2026: $140K published
Quarter from 1 Apr 2026: $150K published
Quarter from 1 Jul 2026: $150K published
Quarter from 1 Oct 2026: $150K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $148K (13 Nov 2026), higher than 99% of its own history.
  • Insider net buying (open market): Insiders sold a net $114.0M in the last 12 months (the 12 months before: -$78.6M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 5 published in the last 12 months, -44% on the 12 months before.
  • Revenue per quarter: Revenue $242.7M in the latest quarter, +55% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 2 sales, $61K; 1 purchase, $148K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
13 Nov 2026Michael R HaydenDirectorBuy5,000$29.64$148KForm 4
19 Oct 2026Shannon L. DeversEVP, Chief Human Resources OfcSellafter exercising options1,357$43.54$59KForm 4
19 Oct 2026Eric SwayzeEVP ResearchSellafter exercising options53$43.54$2KForm 4
31 Jul 2026Michael R HaydenDirectorBuy20,000$52.94$1.1MForm 4
9 Jul 2026Holly B. KordasiewiczEVP, Chief Development OfficerSellplanned in advance (10b5-1)362$84.30$31KForm 4
9 Jul 2026C Frank BennettEVP, Chief Scientific OfficerSellplanned in advance (10b5-1)20,536$84.95$1.7MForm 4
9 Jul 2026Allene M. DiazDirectorSellplanned in advance (10b5-1); after exercising options10,111$85.42$864KForm 4
6 Jul 2026Joseph Klein IIIDirectorSellplanned in advance (10b5-1); after exercising options11,518$79.04$910KForm 4

458 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 61 opened a position, 109 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)24.7M14.9%$1.1B+108K+0.4%
Capital World Investors21.8M13.1%$972.8M+118K+0.5%
BlackRock, Inc.13.2M7.92%$589.1M+2.5M+23%
Vanguard Portfolio Management LLC7.7M4.64%$344.7M-140K-1.8%
Vanguard Capital Management LLC7.2M4.33%$322.3M+7,033+0.1%
Two Sigma Investments, LP6.7M4.04%$300.4M+475K+7.6%
State Street Corp5.7M3.43%$255.0M+1.4M+32%
Royal Bank of Canada4.8M2.89%$214.8M-1.4M-22%
Citadel Advisors LLC4.0M2.42%$179.8M+3.8M17 times as many
Wellington Management Group LLP3.4M2.06%$153.2M-4.2M-55%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 12 Apr 2010. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
12 Apr 2010Department of Health and Human ServicesNational Institutes of Health$0PATHOGEN DIAGNOSTIC PRODUCTS--BIODEFENSE DEVELOPMENTSGrantUSAspending

Company events

All 56 company events

In 12 months: 2 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
8 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
9 Mar 2026Director or officer change8-K
17 Nov 2025Signed a major agreementSame filing: took on new debt, sold shares privately8-K
12 Jun 2025Director or officer change8-K
11 Mar 2025Signed a major agreement8-K
18 Jun 2024Signed a major agreement8-K
29 Feb 2024Director or officer change; Signed a major agreement8-K
18 Dec 2023Signed a major agreement8-K

Reported lobbying spend: $150K in Q3 2026, $150K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Jul 2024NewLMH Strategic Solutionsfor Ionis Pharmaceuticals, Inc.Issues related to the implementation of H.R.5547/S.476 - Maintaining Investments in New Innovation Act and H.R.7384 - Creating Hope Reauthorization Act of 2024.Health issuesFiling
1 Jul 2024NewIonis Pharmaceuticals, Inc.its own lobbyistsIssues related to the implementation of the Inflation Reduction Act. H.R.5547/S.476 - Maintaining Investments in New Innovation Act. H.R.7384 - Creating Hope Reauthorization Act of 2024. H.R.7085 - BIOSECURE Act.Health issues, Medicare/MedicaidFiling
1 Mar 2013NewMcdermott Will & Schulte LLPfor Isis PharmaceuticalsHealth care, patent lawHealth issues, Pharmacy, MEDFiling
28 Sep 2012EndedMcdermott Will & Schulte LLPfor Isis PharmaceuticalsPromote policies and legislation that foster medical research and development, as well as the antisense drug technology which promises relief from potential diseases including cancer, AIDs and diabetes. Specifically, work on patent reform legislation, including S. 23 and H.R. 1249.Pharmacy, Health issues, MEDFiling

The 5 newest of 304 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

14 Aug 2025confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Ionis Pharmaceuticals (IONS): reported revenue of $452.0M for the quarter ended 30 Jun 2025, 2.0× the same quarter last year, while it saw 70 13F filers open a new position in the quarter ended 30 Jun 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Financials: Quarterly revenue change, became public on 31 Jul 2025
  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2025
2023-06-30: $188.4M2023-09-30: $144.2M2023-12-31: $324.5M2024-03-31: $119.5M2024-06-30: $225.2M2024-09-30: $133.8M2024-12-31: $226.6M2025-03-31: $131.6M2025-06-30: $452.0M
The quarter ended 30 Jun 2025 against the 8 quarters before it. this quarterearliernormal: $166.3M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 31 Jul 2025

Ionis Pharmaceuticals reported revenue of $452.0M for the quarter ended 30 Jun 2025, 2.0× the same quarter last year.

This period
$452.0M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$166.3M
Typical spread (median absolute deviation)
$40.8M
How far from its usual level
+4.7
Same quarter last year
$225.2M
History used
3,378 days
2023-06-30: $188.4M2023-09-30: $144.2M2023-12-31: $324.5M2024-03-31: $119.5M2024-06-30: $225.2M2024-09-30: $133.8M2024-12-31: $226.6M2025-03-31: $131.6M2025-06-30: $452.0M
the quarter ended 30 Jun 20258 earlier quartersnormal: $166.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 14 Aug 2025

Ionis Pharmaceuticals saw 70 13F filers open a new position in the quarter ended 30 Jun 2025, 1.6× the same quarter last year.

This period
70 (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
43
Typical spread (median absolute deviation)
2.5
How far from its usual level
+6.3
Same quarter last year
45
History used
3,469 days
2023-06-30: 282023-09-30: 292023-12-31: 572024-03-31: 402024-06-30: 452024-09-30: 452024-12-31: 412025-03-31: 452025-06-30: 70
the quarter ended 30 Jun 20258 earlier quartersnormal: 43

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

21 May 2019confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Ionis Pharmaceuticals (IONS): reported revenue of $297.2M for the quarter ended 31 Mar 2019, 2.1× the same quarter last year, while it saw 79 13F filers open a new position in the quarter ended 31 Mar 2019, 1.9× the same quarter last year. Two unrelated kinds of activity within 7 days.

  • Financials: Quarterly revenue change, became public on 14 May 2019
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2019
2017-03-31: $110.3M2017-06-30: $104.2M2017-09-30: $120.9M2017-12-31: $172.3M2018-03-31: $144.4M2018-06-30: $117.7M2018-09-30: $145.4M2018-12-31: $192.1M2019-03-31: $297.2M
The quarter ended 31 Mar 2019 against the 8 quarters before it. this quarterearliernormal: $132.7M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 14 May 2019

Ionis Pharmaceuticals reported revenue of $297.2M for the quarter ended 31 Mar 2019, 2.1× the same quarter last year.

This period
$297.2M (the quarter ended 31 Mar 2019)
Normal quarter (median of 8 earlier)
$132.7M
Typical spread (median absolute deviation)
$18.6M
How far from its usual level
+6.0
Same quarter last year
$144.4M
History used
3,561 days
2017-03-31: $110.3M2017-06-30: $104.2M2017-09-30: $120.9M2017-12-31: $172.3M2018-03-31: $144.4M2018-06-30: $117.7M2018-09-30: $145.4M2018-12-31: $192.1M2019-03-31: $297.2M
the quarter ended 31 Mar 20198 earlier quartersnormal: $132.7M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 15 May 2019

Ionis Pharmaceuticals saw 79 13F filers open a new position in the quarter ended 31 Mar 2019, 1.9× the same quarter last year.

This period
79 (the quarter ended 31 Mar 2019)
Normal quarter (median of 8 earlier)
35.5
Typical spread (median absolute deviation)
6
How far from its usual level
+4.9
Same quarter last year
42
History used
1,186 days
2017-03-31: 252017-06-30: 352017-09-30: 362017-12-31: 362018-03-31: 422018-06-30: 272018-09-30: 432018-12-31: 302019-03-31: 79
the quarter ended 31 Mar 20198 earlier quartersnormal: 35.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 13 Nov 2026Insiders record

    Hayden Michael R (director) bought 5,000 shares of IONS ($148,200)

  2. 1 Aug 2026Insiders record

    Hayden Michael R (director) bought 20,000 shares of IONS ($1.1M) (dated 31 Jul 2026)

  3. 8 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 8 Jun 2026Filings record

    Director or officer change

  5. 9 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 9 Mar 2026Filings record

    Director or officer change

  7. 17 Feb 2026Institutional holdings change

    saw 93 13F filers open a new position in the quarter ended 31 Dec 2025, 2.3× the same quarter last year.

    Same quarter last year: 41; its normal quarter is 45.

    See the evidence
    This period
    93 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    45
    Typical spread (median absolute deviation)
    4.5
    How far from its usual level
    +7.2
    Same quarter last year
    41
    History used
    3,653 days
    2023-12-31: 572024-03-31: 402024-06-30: 452024-09-30: 452024-12-31: 412025-03-31: 452025-06-30: 702025-09-30: 1002025-12-31: 93
    the quarter ended 31 Dec 20258 earlier quartersnormal: 45

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  8. 14 Nov 2025Institutional holdings change

    saw 100 13F filers open a new position in the quarter ended 30 Sep 2025, 2.2× the same quarter last year.

    Same quarter last year: 45; its normal quarter is 45.

    See the evidence
    This period
    100 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    45
    Typical spread (median absolute deviation)
    4.5
    How far from its usual level
    +8.2
    Same quarter last year
    45
    History used
    3,561 days
    2023-09-30: 292023-12-31: 572024-03-31: 402024-06-30: 452024-09-30: 452024-12-31: 412025-03-31: 452025-06-30: 702025-09-30: 100
    the quarter ended 30 Sep 20258 earlier quartersnormal: 45

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  9. 14 Aug 2025several at once

    reported revenue of $452.0M for the quarter ended 30 Jun 2025, 2.0× the same quarter last year, while it saw 70 13F filers open a new position in the quarter ended 30 Jun 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 31 Jul 2025

    Ionis Pharmaceuticals reported revenue of $452.0M for the quarter ended 30 Jun 2025, 2.0× the same quarter last year.

    This period
    $452.0M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $166.3M
    Typical spread (median absolute deviation)
    $40.8M
    How far from its usual level
    +4.7
    Same quarter last year
    $225.2M
    History used
    3,378 days
    2023-06-30: $188.4M2023-09-30: $144.2M2023-12-31: $324.5M2024-03-31: $119.5M2024-06-30: $225.2M2024-09-30: $133.8M2024-12-31: $226.6M2025-03-31: $131.6M2025-06-30: $452.0M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $166.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2025

    Ionis Pharmaceuticals saw 70 13F filers open a new position in the quarter ended 30 Jun 2025, 1.6× the same quarter last year.

    This period
    70 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    43
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +6.3
    Same quarter last year
    45
    History used
    3,469 days
    2023-06-30: 282023-09-30: 292023-12-31: 572024-03-31: 402024-06-30: 452024-09-30: 452024-12-31: 412025-03-31: 452025-06-30: 70
    the quarter ended 30 Jun 20258 earlier quartersnormal: 43

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  10. 14 Aug 2025Institutional holdings change

    saw 70 13F filers open a new position in the quarter ended 30 Jun 2025, 1.6× the same quarter last year.

    Same quarter last year: 45; its normal quarter is 43.

    See the evidence
    This period
    70 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    43
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +6.3
    Same quarter last year
    45
    History used
    3,469 days
    2023-06-30: 282023-09-30: 292023-12-31: 572024-03-31: 402024-06-30: 452024-09-30: 452024-12-31: 412025-03-31: 452025-06-30: 70
    the quarter ended 30 Jun 20258 earlier quartersnormal: 43

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  11. 31 Jul 2025Financials change

    reported revenue of $452.0M for the quarter ended 30 Jun 2025, 2.0× the same quarter last year.

    Same quarter last year: $225.2M; its normal quarter is $166.3M.

    See the evidence
    This period
    $452.0M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $166.3M
    Typical spread (median absolute deviation)
    $40.8M
    How far from its usual level
    +4.7
    Same quarter last year
    $225.2M
    History used
    3,378 days
    2023-06-30: $188.4M2023-09-30: $144.2M2023-12-31: $324.5M2024-03-31: $119.5M2024-06-30: $225.2M2024-09-30: $133.8M2024-12-31: $226.6M2025-03-31: $131.6M2025-06-30: $452.0M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $166.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  12. 12 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 12 Jun 2025Filings record

    Director or officer change

  14. 3 May 2025Insiders record

    Hayden Michael R (director) bought 15,000 shares of IONS ($477,900) (dated 2 May 2025)

  15. 27 Dec 2024Insiders record

    Hayden Michael R (director) bought 5,000 shares of IONS ($181,075) (dated 26 Dec 2024)

  16. 15 Oct 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MMM', 'TAX']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6275744
  17. 7 Aug 2024Lobbying record

    IONIS PHARMACEUTICALS, INC.: new lobbying registration (LMH STRATEGIC SOLUTIONS) (dated 1 Jul 2024)

  18. 7 Aug 2024Lobbying record

    IONIS PHARMACEUTICALS, INC.: new lobbying registration (in-house) (dated 1 Jul 2024)

  19. 29 Feb 2024Filings record

    Director or officer change

  20. 27 Feb 2024Financials change

    reported revenue of $324.5M for the quarter ended 31 Dec 2023, 2.1× the same quarter last year.

    Same quarter last year: $151.9M; its normal quarter is $148.0M.

    See the evidence
    This period
    $324.5M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $148.0M
    Typical spread (median absolute deviation)
    $13.0M
    How far from its usual level
    +9.2
    Same quarter last year
    $151.9M
    History used
    5,297 days
    2021-12-31: $440.0M2022-03-31: $141.9M2022-06-30: $133.8M2022-09-30: $159.8M2022-12-31: $151.9M2023-03-31: $130.5M2023-06-30: $188.4M2023-09-30: $144.2M2023-12-31: $324.5M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $148.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  21. 14 Dec 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 14 Dec 2023Filings record

    Director or officer change

  23. 15 Aug 2023Financials change

    reported revenue of $188.4M for the quarter ended 30 Jun 2023, 1.4× the same quarter last year.

    Same quarter last year: $133.8M; its normal quarter is $137.9M.

    See the evidence
    This period
    $188.4M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $137.9M
    Typical spread (median absolute deviation)
    $9.7M
    How far from its usual level
    +3.5
    Same quarter last year
    $133.8M
    History used
    5,113 days
    2021-06-30: $125.8M2021-09-30: $133.1M2021-12-31: $440.0M2022-03-31: $141.9M2022-06-30: $133.8M2022-09-30: $159.8M2022-12-31: $151.9M2023-03-31: $130.5M2023-06-30: $188.4M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $137.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  24. 15 Aug 2023Financials change

    spent $12.0M on capital projects in the quarter ended 30 Jun 2023, 3.6× the same quarter last year.

    Same quarter last year: $3.3M; its normal quarter is $3.7M.

    See the evidence
    This period
    $12.0M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $3.7M
    Typical spread (median absolute deviation)
    $826K
    How far from its usual level
    +6.8
    Same quarter last year
    $3.3M
    History used
    5,021 days
    2021-06-30: $4.4M2021-09-30: $3.3M2021-12-31: $2.5M2022-03-31: $2.7M2022-06-30: $3.3M2022-09-30: $5.5M2022-12-31: $4.1M2023-03-31: $10.5M2023-06-30: $12.0M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $3.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  25. 4 Aug 2023Filings record

    A major agreement ended

  26. 9 May 2023Financials change

    spent $10.5M on capital projects in the quarter ended 31 Mar 2023, 3.9× the same quarter last year.

    Same quarter last year: $2.7M; its normal quarter is $3.3M.

    See the evidence
    This period
    $10.5M (the quarter ended 31 Mar 2023)
    Normal quarter (median of 8 earlier)
    $3.3M
    Typical spread (median absolute deviation)
    $818K
    How far from its usual level
    +5.9
    Same quarter last year
    $2.7M
    History used
    4,930 days
    2021-03-31: $1.8M2021-06-30: $4.4M2021-09-30: $3.3M2021-12-31: $2.5M2022-03-31: $2.7M2022-06-30: $3.3M2022-09-30: $5.5M2022-12-31: $4.1M2023-03-31: $10.5M
    the quarter ended 31 Mar 20238 earlier quartersnormal: $3.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  27. 4 Nov 2022Filings record

    A major agreement ended

  28. 24 Oct 2022Filings record

    Completed an acquisition or asset sale

  29. 28 Jul 2022Filings record

    Delisting notice or listing transfer

  30. 16 Jul 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 16 Jul 2022Filings record

    Director or officer change (dated 15 Jul 2022)

  32. 18 Mar 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 18 Mar 2022Filings record

    Director or officer change

  34. 1 Mar 2022Financials change

    reported revenue of $440.0M for the quarter ended 31 Dec 2021, 1.5× the same quarter last year.

    Same quarter last year: $290.3M; its normal quarter is $139.5M.

    See the evidence
    This period
    $440.0M (the quarter ended 31 Dec 2021)
    Normal quarter (median of 8 earlier)
    $139.5M
    Typical spread (median absolute deviation)
    $17.2M
    How far from its usual level
    +11.8
    Same quarter last year
    $290.3M
    History used
    4,567 days
    2019-12-31: $493.7M2020-03-31: $133.4M2020-06-30: $145.5M2020-09-30: $160.1M2020-12-31: $290.3M2021-03-31: $111.6M2021-06-30: $125.8M2021-09-30: $133.1M2021-12-31: $440.0M
    the quarter ended 31 Dec 20218 earlier quartersnormal: $139.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  35. 31 Jan 2022Filings record

    A major agreement ended

  36. 26 Nov 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 26 Nov 2021Filings record

    Director or officer change

  38. 4 Jun 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 4 Jun 2021Filings record

    Director or officer change

  40. 6 Apr 2021Filings record

    Restructuring costs announced

Showing the newest 40 of 69 entries; narrow the window or the kind of data to see older ones.

Not listed: 593 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000874015
Ticker
IONS
Domain
ionis.com
Employer name
IONIS PHARMACEUTICALS, INC. (1 unverified)
Hq location
CA|CARLSBAD|92010 (1 unverified)
Lobbying client
ionis pharmaceuticals, isis pharmaceuticals
Name
Akcea Therapeutics Germany GmbH, a German Corporation, Akcea Therapeutics, Inc., a Delaware Corporation, Akcea Therapeutics Ireland Limited, an Irish Private Company, Akcea Therapeutics Italia S.r.l., an Italian Company and 12 more
Uei
P8PVTLSDNNS6
Wikipedia
Ionis Pharmaceuticals
  • DOL H-1B labor condition applications and PERM certifications160 data points4 Nov 2019 to 21 Sep 2026
  • Federal lobbying disclosures (LDA)4 records, 82 data points30 Jun 2010 to 30 Sep 2026
  • SEC Form 13F institutional holdings5 records, 396 data points31 Dec 2015 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)206 records5 Jan 2016 to 9 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1127 data points31 Dec 2007 to 3 Nov 2026
  • SEC Form 4 insider transactions419 records, 844 data points4 Jan 2016 to 13 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 60 data points30 Oct 2007 to 23 Aug 2019
  • Wikipedia pageviews11 data points11 Nov 2026 to 21 Nov 2026